First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other ant…

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

~Estimated

~$10 – $8,750

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775

Phase 1

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

~Estimated

~$10 – $7,500

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HE…

HER2-positive Metastatic Breast Cancer

~Estimated

~$10 – $750

Abramson Cancer Center at Penn MedicineNCT06551116

QuantumLeap Healthcare CollaborativeNCT05868226